Breaking News Instant updates and real-time market news.

NOW

ServiceNow

$282.57

4.88 (1.76%)

, CELG

Celgene

$108.26

0.07 (0.06%)

04:55
11/21/19
11/21
04:55
11/21/19
04:55

ServiceNow to replace Celgene in S&P 500 at open on 11/21

Bristol-Myers Squibb (BMY) is acquiring Celgene (CELG) in a deal expected to be completed soon pending final conditions

NOW

ServiceNow

$282.57

4.88 (1.76%)

CELG

Celgene

$108.26

0.07 (0.06%)

BMY

Bristol-Myers

$56.38

-0.1 (-0.18%)

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 25

    Mar

  • 04

    Apr

NOW ServiceNow
$282.57

4.88 (1.76%)

11/18/19
JEFF
11/18/19
NO CHANGE
JEFF
Buy
ServiceNow enters 2020 in better leadership position, says Jefferies
Jefferies analyst Samad Samana views the Gina Mastantuono CFO appointment by ServiceNow as a positive, saying it removes uncertainty around a key senior leadership position. The company also announced that Bill McDermott has formally assumed the role of President and CEO. Resolving the leadership situation prior to year-end removes a potential overhang and allows ServiceNow to enter 2020 in a better position, Samana tells investors in a research note. The analyst keeps a Buy rating on the shares with a $280 price target.
10/24/19
BMOC
10/24/19
NO CHANGE
Target $300
BMOC
Outperform
ServiceNow price target lowered to $300 from $315 at BMO Capital
BMO Capital analyst Keith Bachman lowered his price target on ServiceNow to $300, saying the company's Q3 results were "reasonable" despite the "material headwind" in FX. The analyst also cites his management "transition concern" with the move by ServiceNow's CEO to Nike along with the other recent management departures, but he keeps his Outperform rating on the stock and continues to find the company's value proposition as "compelling".
11/08/19
PIPR
11/08/19
INITIATION
Target $305
PIPR
Overweight
ServiceNow assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Rob Owens assumed coverage of ServiceNow with an Overweight rating and $305 price target.
11/04/19
CFRA
11/04/19
UPGRADE
CFRA
Buy
ServiceNow upgraded to Buy from Hold at CFRA
CFRA upgraded ServiceNow to Buy from Hold.
CELG Celgene
$108.26

0.07 (0.06%)

11/01/19
STPT
11/01/19
DOWNGRADE
STPT
Hold
Celgene downgraded to Hold from Buy at Standpoint Research
Standpoint Research analyst Ronnie Moas downgraded Celgene to Hold from Buy.
09/23/19
GUGG
09/23/19
UPGRADE
Target $55
GUGG
Buy
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
Guggenheim analyst Michael Schmidt upgraded Agios Pharmaceuticals (AGIO) to Buy from Neutral following a 20% year-to-date selloff in the shares, stating that the current valuation reflects no value beyond Tibsovo and Idhifa. Even with more conservative estimates, he believes Tibsovo alone is worth $35 per share and Idhifa royalties from Celgene (CELG) are worth $4, giving the stock a one-year "floor valuation" of $39 per share. Meanwhile, feedback from doctors highlights a moderate but "real" commercial opportunity in PKD for Mitapivat, said Schmidt, who set a $55 price target on Agios shares.
11/01/19
BARD
11/01/19
DOWNGRADE
Target $101
BARD
Neutral
Celgene downgraded d to Neutral from Outperform at Baird
Baird analyst Brian Skorney downgraded d to Neutral from Outperform with a $101 price target.
11/01/19
BARD
11/01/19
DOWNGRADE
Target $101
BARD
Neutral
Celgene downgraded to Neutral at Baird
As reported previously, Baird analyst Brian Skorney downgraded Celgene to Neutral from Outperform. The analyst cited its recent upward move and doesn't see any reason for holding the shares ahead of ASH where any hair out the TRANSCEND data could put the entire CVR at risk. Skorney maintained his $101 price target on Celgene shares.
BMY Bristol-Myers
$56.38

-0.1 (-0.18%)

11/07/19
PIPR
11/07/19
NO CHANGE
Target $35
PIPR
Overweight
Nektar price target lowered to $35 from $50 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target for Nektar Therapeutics (NKTR) to $35 from $50 citing trial timeline delays following the company's Q3 results. The analyst, however, keeps an Overweight rating on the shares. Three of six planned registrational trials are ongoing with partner Bristol-Myers (BMY), and management on the call updated the timelines for topline readouts in these trials, which are delayed approximately a year, says Van Buren. He looks forward to the melanoma/PIVOT-02 cohort update at SITC this weekend and is "encouraged to see more of the pipeline advance into clinical development," saying Nektar continues to diversify beyond bempeg.
08/27/19
RBCM
08/27/19
NO CHANGE
Target $206
RBCM
Sector Perform
Amgen price target raised to $206 from $192 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Amgen to $206, saying that despite the "sticker shock" of its $13.4B deal for the Otezla franchise, the transaction is expected to be immediately accretive to earnings and fitting well with its existing inflammation and immunology portfolio. The analyst believes that Amgen should be able to grow revenue "majorly" over the next 3 years as it leverages Otezla potential with its legal victory on Enbrel, stating that there is a case for its multiple to re-rate higher. MacKay keeps his Sector Perform rating on Amgen shares as he awaits for its emerging pipeline to also "fill the shoes" of its maturing assets.
10/16/19
BOFA
10/16/19
INITIATION
Target $60
BOFA
Buy
Bristol-Myers reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Bristol-Myers with a Buy rating and $60 price target. The analyst said overall he is bullish on the combined company, citing "several higher-impact catalysts on the horizon" that could result in a re-rating the stock.
11/20/19
JPMS
11/20/19
NO CHANGE
Target $64
JPMS
Overweight
Bristol-Myers adjuvant melanoma update a 'minor setback,' says JPMorgan
After Bristol-Myers announced that the CM-915 study of Opdivo+Yervoy vs. Opdivo in adjuvant melanoma did not meet its co-primary endpoint in a patient subset, JPMorgan analyst Chris Schott said it is important to note that the study will continue unchanged to assess recurrence-free survival in the broader all-comers intention-to-treat population. He also noted that Bristol maintains a market leading position for Opdivo+/-Yervoy in metastatic melanoma as well as Opdivo in the adjuvant setting, stating that the CM-915 study looks to move the O/Y combo to the adjuvant setting. He calls today's update a "minor setback," but emphasizes both the high bar for the combo versus Opdivo monotherapy and the fact that his estimates do not reflect Yervoy sales in this setting. Schott maintains an Overweight rating on Bristol-Myers shares.

TODAY'S FREE FLY STORIES

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

07:01
12/09/19
12/09
07:01
12/09/19
07:01
Recommendations
Agios Pharmaceuticals analyst commentary  »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

CI

Cigna

$198.96

3.44 (1.76%)

07:00
12/09/19
12/09
07:00
12/09/19
07:00
Conference/Events
Cigna management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 06

    Feb

AMAT

Applied Materials

$56.60

0.77 (1.38%)

06:59
12/09/19
12/09
06:59
12/09/19
06:59
Conference/Events
Applied Materials management to meet with UBS »

Breakfast Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CGC

Canopy Growth

$18.65

0.07 (0.38%)

, STZ

Constellation Brands

$183.60

1.13 (0.62%)

06:58
12/09/19
12/09
06:58
12/09/19
06:58
Recommendations
Cantor sees over 66% chance of Constellation bidding for Canopy Growth »

Cantor Fitzgerald analyst…

CGC

Canopy Growth

$18.65

0.07 (0.38%)

STZ

Constellation Brands

$183.60

1.13 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

MTG

MGIC Investment

$14.10

-0.03 (-0.21%)

06:58
12/09/19
12/09
06:58
12/09/19
06:58
Hot Stocks
MGIC Investment issues November operating statistics »

MGIC Investment issued an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ZION

Zions Bancorp

$49.71

0.43 (0.87%)

06:56
12/09/19
12/09
06:56
12/09/19
06:56
Conference/Events
Zions Bancorp management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

EGRX

Eagle Pharmaceuticals

$56.38

0.85 (1.53%)

06:55
12/09/19
12/09
06:55
12/09/19
06:55
Hot Stocks
Eagle Pharmaceuticals commences dosing in pilot study of fulvestrant »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YY

YY

$58.68

-0.7 (-1.18%)

06:54
12/09/19
12/09
06:54
12/09/19
06:54
Conference/Events
YY management to meet with Benchmark »

Group Breakfast Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

THO

Thor Industries

$67.76

2.17 (3.31%)

06:54
12/09/19
12/09
06:54
12/09/19
06:54
Earnings
Thor Industries reports Q1 EPS 92c, consensus $1.23 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

WTER

Alkaline Water

$1.13

0.01 (0.89%)

06:51
12/09/19
12/09
06:51
12/09/19
06:51
Conference/Events
Alkaline Water management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

FTV

Fortive

$72.86

0.5 (0.69%)

06:50
12/09/19
12/09
06:50
12/09/19
06:50
Upgrade
Fortive rating change  »

Fortive upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MRK

Merck

$88.84

0.09 (0.10%)

, ARQL

ArQule

$9.67

0.15 (1.58%)

06:49
12/09/19
12/09
06:49
12/09/19
06:49
Hot Stocks
Merck to acquire ArQule for $20 per share, or approximately $2.7B »

Merck (MRK) and ArQule…

MRK

Merck

$88.84

0.09 (0.10%)

ARQL

ArQule

$9.67

0.15 (1.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 11

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

COLD

Americold Realty Trust

$37.09

-0.31 (-0.83%)

06:49
12/09/19
12/09
06:49
12/09/19
06:49
Downgrade
Americold Realty Trust rating change  »

Americold Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETNB

89bio

$28.38

0.86 (3.13%)

06:48
12/09/19
12/09
06:48
12/09/19
06:48
Initiation
89bio initiated  »

89bio initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$151.77

1.85 (1.23%)

, DELL

Dell Technologies

$47.09

-0.255 (-0.54%)

06:48
12/09/19
12/09
06:48
12/09/19
06:48
Periodicals
China orders state offices to remove foreign hardware, software, FT reports »

China's Communist…

MSFT

Microsoft

$151.77

1.85 (1.23%)

DELL

Dell Technologies

$47.09

-0.255 (-0.54%)

HPQ

HP Inc.

$20.50

0.17 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 11

    Dec

  • 27

    Feb

WCC

Wesco

$55.24

1.14 (2.11%)

06:48
12/09/19
12/09
06:48
12/09/19
06:48
Conference/Events
Wesco management to meet with KeyBanc »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 11

    Dec

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

06:46
12/09/19
12/09
06:46
12/09/19
06:46
Recommendations
Corvus Pharmaceuticals analyst commentary  »

Corvus pipeline updates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRL

Charles River

$146.23

1.765 (1.22%)

06:45
12/09/19
12/09
06:45
12/09/19
06:45
Recommendations
Charles River analyst commentary  »

Charles River price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY-R

Bristol-Myers Squibb CVR

$0.00

(0.00%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

06:42
12/09/19
12/09
06:42
12/09/19
06:42
Recommendations
Bristol-Myers Squibb CVR, Bristol-Myers analyst commentary  »

Bristol-Myers Squibb CVR…

BMY-R

Bristol-Myers Squibb CVR

$0.00

(0.00%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

MRNS

Marinus Pharmaceuticals

$1.32

0.06 (4.76%)

06:39
12/09/19
12/09
06:39
12/09/19
06:39
Hot Stocks
Marinus Pharmaceuticals provides update on orphan seizure programs »

Marinus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOW

Dow Inc.

$53.25

1.24 (2.38%)

06:39
12/09/19
12/09
06:39
12/09/19
06:39
Upgrade
Dow Inc. rating change  »

Dow Inc. upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRA

Kraton

$23.04

0.63 (2.81%)

06:39
12/09/19
12/09
06:39
12/09/19
06:39
Upgrade
Kraton rating change  »

Kraton upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STZ

Constellation Brands

$183.60

1.13 (0.62%)

, CGC

Canopy Growth

$18.65

0.07 (0.38%)

06:38
12/09/19
12/09
06:38
12/09/19
06:38
Hot Stocks
Constellation Brands appoints Garth Hankinson as CFO »

Constellation Brands…

STZ

Constellation Brands

$183.60

1.13 (0.62%)

CGC

Canopy Growth

$18.65

0.07 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

VIAC

ViacomCBS

$39.70

-1.08 (-2.65%)

06:38
12/09/19
12/09
06:38
12/09/19
06:38
Initiation
ViacomCBS initiated  »

ViacomCBS reinstated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THC

Tenet

$35.53

1.255 (3.66%)

06:37
12/09/19
12/09
06:37
12/09/19
06:37
Upgrade
Tenet rating change  »

Tenet upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.